These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 30069872)

  • 1. The Case for Restructuring the Medicare Prescription Drug Benefit.
    Frakt A; Miller M
    Health Serv Res; 2018 Dec; 53(6):4132-4137. PubMed ID: 30069872
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2008 Jan; ():1-23. PubMed ID: 18345558
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2009 Jan; ():1-26. PubMed ID: 19301435
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmaceuticals and medical devices: Medicare Part D. Issue brief.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-32. PubMed ID: 23297447
    [No Abstract]   [Full Text] [Related]  

  • 5. Medicare program; Medicare prescription drug benefit. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2005 Jan; 70(18):4193-585. PubMed ID: 15678603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceuticals and medical devices: Medicare Part D.
    ; Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-37. PubMed ID: 22403844
    [No Abstract]   [Full Text] [Related]  

  • 7. Medicare program; establishment of the Medicare advantage program. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2005 Jan; 70(18):4587-741. PubMed ID: 15678604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of Medicare Part D prescription drug benefit: potential implications for patients with psychotic disorders.
    Rosenberg JM
    Am J Health Syst Pharm; 2007 Jan; 64(2 Suppl 1):S18-23; quiz S24-5. PubMed ID: 17215472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceuticals and medical devices: Medicare Part D.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-32. PubMed ID: 24482890
    [No Abstract]   [Full Text] [Related]  

  • 10. Medicare program; changes to the requirements for Part D prescribers. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2015 May; 80(87):25958-66. PubMed ID: 25985480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaceuticals and Medical Devices: Medicare Part D.
    Steiner DJ;
    Issue Brief Health Policy Track Serv; 2015 Dec; ():1-31. PubMed ID: 27116795
    [No Abstract]   [Full Text] [Related]  

  • 12. Changing Medicare's Protected Classes: History, Mistrust, and Budgets in the Prescription Drug Market.
    Frank RG
    Psychiatr Serv; 2019 Oct; 70(10):858-859. PubMed ID: 31480929
    [No Abstract]   [Full Text] [Related]  

  • 13. Paying for Drugs After the Medicare Part D Beneficiary Reaches the Catastrophic Limit: Lessons on Cost Sharing from Other US Policy Partnerships Between Government and Commercial Industry.
    Padula WV; Ballreich J; Anderson GF
    Appl Health Econ Health Policy; 2018 Dec; 16(6):753-763. PubMed ID: 30058011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medicare program; Medicare Advantage and prescription drug benefit programs: negotiated pricing and remaining revisions. Final rule with comment period.
    Fed Regist; 2009 Jan; 74(7):1493-549. PubMed ID: 19143114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specialty Drugs - A Distinctly American Phenomenon.
    Naci H; Kesselheim AS
    N Engl J Med; 2020 Jun; 382(23):2179-2181. PubMed ID: 32492301
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmaceuticals and medical devices: cost savings. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2008 Jan; ():1-27. PubMed ID: 18345555
    [No Abstract]   [Full Text] [Related]  

  • 18. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
    Yazdany J; Dudley RA; Chen R; Lin GA; Tseng CW
    Arthritis Rheumatol; 2015 Jun; 67(6):1474-80. PubMed ID: 25900105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medicare reform: a look at the house ways and means proposal.
    Sangji NF; Hedstrom J; Meara JG; Martin MB
    Bull Am Coll Surg; 2014 Feb; 99(2):10-8. PubMed ID: 24564016
    [No Abstract]   [Full Text] [Related]  

  • 20. Medicare program; modification to the weighting methodology used to calculate the low-income benchmark amount. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2008 Apr; 73(65):18176-82. PubMed ID: 18464346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.